[ad_1]
Corcept Therapeutics Included (NASDAQ:CORT) is without doubt one of the Shares That May Mint Millionaires in 2026.
On December 16, UBS analyst Ashwani Verma initiated protection of Corcept Therapeutics Included (NASDAQ:CORT) inventory with a Impartial ranking and $95 value goal. In an investor notice, the analyst cited valuation for the Impartial ranking, with the shares up 64% year-to-date. Per the analyst, the inventory was already pricing in each the continued development in hypercortisolism and Corcept’s new launch alternative in platinum-resistant ovarian most cancers.
In early November, the corporate posted earnings for the third quarter of 2025, reporting earnings per share of $0.16, beating market estimates by $0.02. The income over the interval was greater than $207 million, up near 14% in comparison with the income over the identical interval final 12 months and lacking analyst expectations by near $11 million. The agency additionally modified 2025 income steerage of $800 to $850 million versus the $852 million consensus.
Corcept Therapeutics Included (NASDAQ:CORT) engages within the discovery and improvement of medicines for the therapy of extreme endocrinologic, oncologic, metabolic, and neurologic issues in america.
Whereas we acknowledge the potential of CWAN as an funding, we imagine sure AI shares supply larger upside potential and carry much less draw back threat. In case you’re in search of a particularly undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring development, see our free report on the greatest short-term AI inventory.
READ NEXT: 15 Dividend Shares Paying 4%+ Yield in 2025 and 14 Greatest US Shares to Purchase for Lengthy Time period
Disclosure: None.
[ad_2]
